Peptide Blends
CagriSema (5mg+5mg)
CagriSema (5mg+5mg) — research-grade reference material, supplied in multiple sizes.
- Product Code
- CS
- Purity
- 99%
- Form
- Lyophilized powder
- Packaging
- 10mg*10vials
Ships from multiple warehouses — typically 2–5 business days to nearby destinations. International orders coordinated per destination.
No prices are published. Available scope, specifications and documentation are confirmed during specification review. Supplied for research and analytical use by qualified organizations — see our Research Use Only policy.
Specification
- Purity specification
- 99%
- Available sizes
- 10mg × 10vials
- Storage
- 2–8 °C, away from light and moisture
- MOQ
- On request
Research Applications
- A mid-dose research combination of cagrilintide (amylin analog) and semaglutide (GLP-1 receptor agonist) for weight-loss mechanism studies.
- Dual amylin/GLP-1 receptor activation is studied for additive effects on gastric emptying, satiety signaling, and food intake.
- Research applications include metabolic and glycemic-control models evaluating the synergistic metabolic benefits of the combination.
- Used to investigate whether concurrent amylin and GLP-1 agonism enhances weight reduction beyond monotherapy in preclinical settings.
Cagrilintide + Semaglutide combination, synergistic metabolic-research effect
Send us your specification
Share your sequence, format, packaging and documentation needs. Our team will review scope and next project steps.